The last two decades have seen a lot of development in the area of surrogate marker validation. One of these approaches places the evaluation in a meta-analytic framework, leading to definitions in terms of trial-and individual-level association. A drawback of this methodology is that different settings have led to different measures at the individual level. Using information theory, Alonso et al. proposed a unified framework, leading to a new definition of surrogacy, which offers interpretational advantages and is applicable in a wide range of situations. In this work, we illustrate how this information-theoretic approach can be used to evaluate surrogacy when both endpoints are of a time-to-event type. Two meta-analyses, in early and advanced colon cancer, respectively, are then used to evaluate the performance of time to cancer recurrence as a surrogate for overall survival.
Introduction
Information theory is a relatively new branch of the mathematical theory of probability and statistics, made mathematically rigorous only from 1940s onwards. The term information theory does not have a unique definition. Broadly speaking, information theory deals with the study of problems concerning any system. In fact, it has been applied in a variety of fields and plays a prominent role in modern communication theory, which formulates a communication system as a stochastic or random process.
The theory has its mathematical roots connected with the idea of disorder or entropy used in thermodynamics and statistical mechanics. Some of the first attempts for formalizing these information-theoretic ideas were undertaken by Nyquist 1 and Hartley, 2 who recognized the logarithmic nature of the measure of information. A major contribution in this area came in 1948 3 when Shannon published a remarkable paper on the properties of information sources, and the communication channels used to transmit the output of these sources.
The fundamental quantities of information theory, entropy, relative entropy and mutual information, are defined as functionals of probability distributions and can be placed within a probabilistic framework. Fisher's 4 measure of the amount of information supplied by data about an unknown parameter is well known to statisticians. This measure is the first use of information in mathematical statistics and was introduced especially for the theory of statistical estimation. A quarter of a century later, Kullback and Leibler 5 studied another measure of information from a statistical point of view, involving two probability distributions associated with the same experiment. Other proposals to measure information have appeared in the literature over the last 20 years.
Alonso et al. 6 used information-theoretic ideas to introduce a new and simple definition of surrogacy that possesses an appealing interpretation. This link between information theory and surrogate marker evaluation allows us to approach the validation problem in a unified way when the true and surrogate endpoints are of a different nature. In this present work, we illustrate how this information-theoretic approach can be applied when both the surrogate and the true endpoint are of a time-to-event type.
Section 2 summarizes some of the main developments that have appeared in the surrogate marker literature over the last 20 years. In Section 3, we introduce the informationtheoretic approach to surrogate marker evaluation. In Section 4, the methodology presented in Section 3 is applied to evaluate time-to-cancer recurrence as a surrogate marker for overall survival in early and advanced colon cancer.
Surrogate marker validation
The endpoint chosen to evaluate the efficacy of a new treatment is one of the most important factors influencing the complexity and duration of modern clinical trials. Frequently, the most sensible and relevant clinical endpoint, the so-called 'true' endpoint (T), is difficult to use in a clinical trial, for example, when its use would imply risky manipulations of the patient or would increase the duration and/or cost of the study. In such situations, an attractive and sensible solution is to replace the 'problematic' true endpoint by another one that can be measured more conveniently, a so-called 'surrogate' endpoint (S).
In a seminal paper, Prentice 7 provided a definition and a set of criteria that have formed the basis for a lot of subsequent work. Freedman et al. 8 introduced the proportion of treatment explained to quantify how much of the treatment effect on the true endpoint is captured by the surrogate endpoint. Buyse and Molenberghs 9 decomposed the proportion of treatment explained into the relative effect and the adjusted association, and argued in favor of these quantities instead. These proposals were formulated assuming that the validation of a surrogate is based on data from a single randomized clinical trial. This, however, leads to problems with untestable assumptions and too low a statistical power. To overcome these problems, Albert et al. 10 suggested to combine the information from several groups of patients, such as, for example, multicenter trials or meta-analyses. Approaches following these ideas were implemented by Daniels et al., 11 Gail et al. 12 and Buyse et al. 13 The latter suggested a multi-trial approach that led to a new definition of surrogacy in terms of the quality of both trialand individual-level association between the surrogate and the true endpoint. In their approach, the quality of a surrogate at the trial level is assessed by means of a coefficient of determination R 2 trial . At the individual level, the squared correlation R 2 ind between the surrogate and true endpoint, after adjustment for both the trial effects and the treatment effects, is used.
In this meta-analytic scenario, several individual-level measures have been proposed. In the binary-binary setting, Renard et al. 14 used the correlation between two latent variables R 2 ind = corr(S,T) to define individual-level surrogacy and alternatively defined R 2 ind = ψ, the global odds ratio between both endpoints estimated from a bivariate Plackett-Dale model. When the true endpoint is a survival time and the surrogate is a longitudinal sequence, Renard et al., 15 using Henderson's model, proposed to study the individual level based on a time function defined as R 2
is a latent bivariate Gaussian process. When both responses are measured longitudinally, the so-called variance reduction factor (VRF), a canonicalcorrelation based quantity θ p , and R 2 have been proposed to evaluate surrogacy. 16, 17 Additionally, the VRF, θ p and R 2 can be incorporated into a more general framework allowing for interpretation in terms of canonical correlations of the error vectors, based on which these authors defined different families of individual-level parameters. Other proposals have been suggested in other settings.
All of these examples clearly show one of the main limitations of the meta-analytic methodology so far: different settings require different definitions. For some of these settings, researchers have proposed to estimate the association between both endpoints at a certain latent level, which, although mathematically convenient, can be clinically less relevant or difficult to interpret. Moreover, in all the previous cases, a joint model for both endpoints needs to be fitted. This can represent a very serious computational burden in many practical situations and, in addition, most of these models are not implemented in standard software packages rendering the methodology difficult to apply.
To overcome these limitations, Alonso et al. 16 used information theory to create a unified framework, leading to a definition of surrogacy with an intuitive interpretation and applicable in a wide range of situations. Their approach also enhances insight into the chances of finding a good surrogate endpoint in a given situation. They further showed that some of the previous proposals follow as special cases of this informationtheoretic approach. In the following section, we outline this methodology.
Information-theoretic approach
Alonso et al. 16 propose to term S a good surrogate for T at the individual level if uncertainty about T is reduced by a 'large' amount when S is known; the corresponding definition for the trial level is that a good surrogate implies that the uncertainty about the effect of treatment on T is reduced by knowledge about the effect of treatment on S. These definitions, in spite of being based on formal concepts rooted in information theory, are simple and intuitive. Note that the general idea behind surrogacy is to reduce the uncertainty, or equivalently, to gain information about a 'problematic' true endpoint through the use of a surrogate. At the trial level, the situation is similar: we want to gain information about the unobserved treatment effect on the true endpoint using the treatment effect on the surrogate.
To quantify the proportion of the uncertainty about the true endpoint that the surrogate can explain, these authors proposed to use the so-called R 2 h , defined as:
where EP(X) = (1/(2πe) n )e 2h(X) denotes the so-called power entropy of the random variable X with density function f and h denotes its entropy defined as h(X) = E[− log f (X)]. Note that Z represents treatment allocation. When the conditional distribution of T (and/or S), given Z differs substantially from the marginal distribution of T (and/or S), it follows that a substantial portion of the total variability in the outcome is explained by treatment. R 2 h satisfies a number of useful properties:
is invariant under bijective transformations of T and S, in the sense that there is a 'one-to-one onto' mapping between S and T; (v) When R 2 h −→ 1 for continuous models, there is usually some degeneracy appearing in the distribution of (T, S), that is, often T = φ(S) for some nontrivial function φ. The latter means that there then exists a deterministic relationship between T and S. In a meta-analytic framework with N clinical trials, one could have different, trial-specific R 2 hi . In this setting, a plausible approach is to use a meta-analytic R 2 h defined as
The α i 's could be chosen to represent (un)weighted averages of the trial-specific individual-level surrogacies R 2 hi , to produce an overall individual-level surrogacy. Many choices for the α i 's are possible, giving rise to a family of measures. Clearly, these calculations require data on S and T to be available from all trials. Similar families have been proposed to evaluate individual level surrogacy in other settings. 17 In the following section, we will apply these ideas to analyse the two case studies.
Analysis of the case studies
In this section, we will use the meta-analytic framework described in section 2 to evaluate the performance of time-to-cancer recurrence as a surrogate marker for overall survival using data from two meta-analyses in early 18 and advanced colon cancer. 19 This meta-analytic approach identifies two dimensions in the surrogate marker problem, that is, the trial and individual dimension. The information-theoretic measure R 2 h can be used to measure either the individual-or trial-level surrogacy (depending on the context); the calculations at each of the levels are similar but different. This approach has advantages over previously introduced measures, such as the R 2 trial and R 2 ind introduced by Buyse et al., 13 because it can be applied to a wide variety of data types.
We therefore approach the problem using the information-theoretic methodology introduced in Section 3 and use the R 2 h to quantify the individual-and trial-level surrogacies. It is important to point out that, when applied at the trial level, and assuming a linear functional relationship between the pairs of trial-specific treatment effects on the true and surrogate endpoints, respectively, the R 2 h equals the R 2 trial . This equality allows us to give a new interpretation to the R 2 trial . Indeed, the R 2 trial can now be interpreted as the proportion of all the uncertainty about the treatment effect on the true endpoint that will be explained by the treatment effect on the surrogate. When a more complex functional form is necessary to describe the relationship between both treatment effects at the trial level, the R 2 trial becomes inapplicable, given the fact that the linear mixed model behind the calculations might be overly simple, and hence the R 2 h is a viable alternative to quantify surrogacy at the trial level as well. This illustrates that the surrogacy measures proposed by Buyse et al. 13 can be seen as special cases of the more general framework based on the information-theoretic approach previously presented.
Advanced colon cancer
The analysis was based on data coming from 10 clinical trials in advanced colon cancer. 19 To evaluate the trial-level surrogacy, two different approaches were used. In the first approach, two independent proportional hazard models were fitted at the first stage within each trial for the surrogate and the true endpoint, respectively. These models only included the treatment variable indicator, Z, as a covariate. In the second stage, the maximum likelihood estimates of the trial specific treatment effects on true endpoint (β i ) and the surrogate (α i ) were used to estimate the R 2 trial , which is the same as the version of the R 2 h used at the trial level in this case. The latter fact has been established in ref. 16 .
In the second approach, the association between both endpoints was taken into account by fitting a shared gamma frailty model within each trial at the first stage. The previous procedure is equivalent to using a Clayton copula with margins modeled using a proportional hazard regression. Here again, in the second stage, the maximum likelihood estimates of the trial-specific treatment effects were used to quantify the trial-level surrogacy.
To evaluate the individual-level surrogacy, we first defined a time-dependent covariate S(t) that takes value 0 until the surrogate endpoint occurs and 1 thereafter. The following two models were fitted:
where i denotes the trial and j denotes the subject. Using these two models, Alonso et al. 6 showed that under some general conditions, R 2 h can be estimated using the so-called likelihood reduction factor introduced in ref. 20 . Table 1 displays the results for both the trial-and individual-level surrogacy. At the trial level, some convergency problems were encountered, when fitting the Clayton copula model to data from one particular trial, and therefore the results shown in the table are calculated excluding this trial. Both approaches used to quantify trial-level surrogacy, that is, using separate models on the one hand and the Clayton copula on the other hand, lead to similar point estimates. These point estimates hint on the presence of a large association at the trial level. However, the wide confidence intervals obtained in both cases do not rule out a weaker association.
When the problematic trial was taken into account, the approach using independent Cox models produced aR 2 trial = 0.82 (CI = [0.40; 0.95]) and at the individual levelR 2 h = 0.84 (CI = [0.82; 0.85]). Clearly, the inclusion of this trial seems to have an important impact on the individual-level surrogacy while less so at the trial level. A closer exploration of the trial-producing convergency problems showed that in this study, the time between cancer recurrence and death was considerably smaller. However, whether this trial is included or not, we always observed a large value of R 2 h indicating that the surrogate can explain a large proportion (more than 76%) of our uncertainty about the true endpoint.
Early colon cancer
This meta-analysis contains data coming from more than 10 000 patients included in 10 early colon cancer trials. 21 Like in the previous case study, the analysis was again based on data coming from 10 clinical trials in early colon cancer. The same approaches used in the previous example were applied to evaluate the trial-and individual-level surrogacy. Table 2 summarizes the results. Here again, a very strong association was observed at the individual level. The large value obtained for the R 2 h indicates that time-to-cancer recurrence can explain more than 84% of the uncertainty about the survival of the patient. Once again, large point estimates for R 2 trial were observed, notwithstanding the wide confidence intervals hamper our interpretation of these point estimates.
Discussion
Based on a meta-analytic paradigm, Alonso et al. 6 introduced an information-theoretic approach to evaluate surrogacy. This approach leads to a simple yet meaningful definition of surrogacy and offers a unified approach to surrogate marker evaluation.
While the R 2 measures, coming from the framework of Buyse et al., 13 do not readily generalize to settings with non-normal outcomes, the R 2 h applies to a wide variety of settings (normal, binary, categorical and longitudinal outcomes) and reduces, in all of these specific settings, to the quantities previously introduced in the literature. This provides a theoretical basis for the scattered set of proposals made earlier in the literature.
In this work, we have used this information-theoretic approach to evaluate the performance of time-to-cancer recurrence as a surrogate marker for overall survival using data from two meta-analyses in early 18 and advanced colon cancer. 19 In both cases, a very strong association was found at the individual level, clearly showing that the surrogate can explain more than 76 and 84% of our total uncertainty about the overall survival for advanced and early colon cancer, respectively.
At the trial level, even though large point estimates of the R 2 trial were obtained, the associated confidence intervals were relatively wide, hampering interpretation.
A number of additional issues require attention. First, when there are more than two arms in the clinical trials under consideration, one has the choice between calculating the validation measures using all arms simultaneously. Indeed, the information-theoretic developments carry through when Z represents a nominal covariate or, equivalently, a set of dummies, rather than a sole binary variable. Alternatively, the measures can be calculated for every pair of arms deemed of interest. Second, when several trials are included into a meta-analysis, it is implicitly assumed that the arms are properly ordered. Such a situation arises, for example, when in all trials the control arms, on the one hand, and the active arms, on the other hand, are similar. Otherwise, application of the methodology can become quite cumbersome, or even arbitrary. Third, even though the measures provide a quantification of surrogacy, there remains the important question as to how large is large. It is tough to provide hard guidance and, arguably, decisions will have to be taken based on a number of quantitative and qualitative arguments combined. Finally, note that, by parsimoniously using information, the information-theoretic approaches may lead to tighter confidence intervals than in the hierarchical-model framework. This is an advantage, in addition to increased generality and flexibility.
